 Vaxart Incs NASDAQ: VXRT has disclosed data from a 12-subject Phase 1b blinded study evaluating the ability of its oral norovirus vaccine to boost immunogenicity. Study participants were initially vaccinated with Vaxarts oral norovirus vaccine in late 2019 and were vaccinated again between February and April 2021. 